1022956-26-8

Basic information

• Product Name: 2-((2,5-dichloropyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide
• Synonyms: 2-((2,5-dichloropyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide
• CAS NO: 1022956-26-8
• Molecular Weight: 347.225
• Mol File: 1022956-26-8.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 2-((2,5-dichloropyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((2,5-dichloropyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide(1022956-26-8)
• EPA Substance Registry System: 2-((2,5-dichloropyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide(1022956-26-8)

Safety Data

• Hazardous Substances Data: 1022956-26-8(Hazardous Substances Data)

Usage

Type of compound

Sulfonamide derivative

Contains

Dichloropyrimidine moiety, dimethylbenzene sulfonamide group

Usage

Intermediate in the synthesis of pharmaceutical compounds

Known for

Antibacterial properties, frequently used as antibiotics

Potential applications

Antibacterial and antimicrobial medications

Value in research and development

Unique structure makes it a valuable tool in the pharmaceutical industry

Upstream product

• 23530-43-0 2-(N,N-dimethylaminosulfonyl)nitrobenzene 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 54468-86-9 2-amino-N,N-dimethyl-benzenesulfonamide 
• 5750-76-5 2,4,5-trichloropyrimidine 

Downstream Products

• 1341200-45-0 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide 
• 1341200-61-0 5-fluoro-4-(4-fluoro-2-(pyrrolidin-1-ylsulfonyl)phenyl)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)pyrimidin-2-amine 
• 1341200-60-9 2-((5-chloro-2-((4-(methyl(1-methylpiperidin-4-yl)amino)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide 

Relevant articles and documents

Discovery of a potent dual ALK and EGFR T790M inhibitor

The mutational activations of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) are validated oncogenic events and the targets of approved drugs to treat non-small cell lung cancer (NSCLC). Here we report highly potent dual small molecule inhibitors of both ALK and EGFR, particularly the T790M mutant which confers resistance to first generation EGFR inhibitors. Dual ALK/EGFR inhibitors may provide an efficient approach to prevent resistance that arises as a consequence of clinically reported reciprocal activation mechanisms. Our lead compound 7c displayed remarkable inhibitory activities against both ALK and EGFR in enzymatic and cellular assays. We demonstrate that 7c is capable of recapitulating the signaling effects and antiproliferative activity of combined treatment with the approved ALK inhibitor ceritinib and T790M EGFR inhibitor osimertinib against patient-derived non-small cell lung cancer cell line, DFCI032 which harbors both EML4-ALK and activated EGFR.

Small molecule inhibitors of leucine-rich repetitive kinase 2 and their applications

The present invention provides a small molecule inhibitor of leucine-rich repetitive kinase 2 and applications thereof; compounds as small molecule inhibitors such as compounds shown in formula I of the present invention or isotopic forms thereof, stereoisomers, tautomers, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, hydrates, prodrugs and polymorphs. The compound has a high LRRK2 inhibitory activity and has high application value in the preparation of drugs for the treatment of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and other diseases.

AXL KINASE INHIBITORS AND USE OF THE SAME

Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrat

POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITOR

Provided is a polycyclic inhibitor of anaplastic lymphoma kinase as represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, and ring A are as defined in the description. The invention also relates to a method for preparing the compound, a pharmaceutical preparation and a pharmaceutical composition comprising the compound, and use of the compound, the pharmaceutically acceptable salt or stereoisomer thereof in manufacture of a medicament for the treatment and/or prevention of an anaplastic lymphoma kinase-mediated cancer or non-cancer related diseases.